Portfolio
The Amphion model has been used to create industry leading and market transforming companies as shown scrolling above. In addition, some of our current active investments are listed below:
Motif BioSciences, Inc.
Motif is a development-stage population genetics company.
WellGen, Inc.
WellGen uses nutrigenomics to develop products to treat disease.
Beijing Med-Pharm Co. Ltd.
Beijing Med-Pharm is a distributor of pharmaceuticals in China.
AXCESS International, Inc.
Axcess provides RFID (radio frequency identification) systems.
FireStar Software
FireStar Software, Inc. provides software for financial services payment transactions.
Durham Scientific Crystals Limited (DSC)
DSC produces specialty semiconductors for medical and security imaging.
m2m Imaging
m2m Imaging Corporation develops and manufactures clinical and preclinical devices for imaging applications.
Myconostica
Myconostica Ltd. is a University of Manchester spin-out company specialising in molecular diagnostic tests for life-threatening respiratory fungal infection.
Motif BioSciences, Inc.
Motif BioSciences Inc. ("Motif") works with a variety of founder populations in the Persian Gulf region and elsewhere to discover genes involved in illness and wellness. Motif has developed a specialised (patent-pending) methodology for collecting and analysing genetic data.
Over the next five years, more than half of the world's top selling drugs will go off patent. Between 2007 and 2011, drug companies stand to lose US $28 billion due to expiring patents. As a result, pharmaceutical companies have a significant need to develop their new product pipelines. By applying discoveries made possible by the mapping of the human genome and utilising Motif's specialised genetic technology, researchers will be able to better understand the underlyingmechanisms of hard-to-treat diseases and develop validated drug targets for new therapies. The market for new type II diabetes drugs is US $20 billion, the market for new cancer drugs is US $44 billion, and the market for new heart disease drugs is US $25 billion.
Amphion's fully-diluted ownership stake in Motif was 41.17% as of 31 December 2006.
Management
Zaki Hosny, Chief Executive Officer
Dr. Clay Stephens, Senior Vice President and Chief Scientific Officer
Kevin Arnold, Executive Director, Industrial Genetics
Board of Directors
Richard C.E. Morgan, Chairman - Chief Executive Officer, Amphion Innovations plc
Omar Ghobash - Deputy Chief Executive Officer, Emirates Foundation
Jon Gold - Senior Financial Analyst, Federated Investments Inc.
Gerald Moufflet - Chief Executive Officer and President, Acceleration International
Dr. Mary Lake Polan - Professor and Chair Emeritus, Department of Obstetrics and Gynecology,
Stanford University School of Medicine
Dr. John W. Stakes - Director Specialty Care Development, Harvard Medical School and
Massachusetts General Hospital
Bruce Williams - Senior Vice President Global Business Management, Enzon Pharmaceuticals
Wellgen, Inc.
WellGen, Inc. ("WellGen") applies proprietary nutrigenomics technology to the discovery of food and dietary supplement ingredients from plants and foods for the health and wellness markets. WellGen is a spin out of Rutgers University and has an exclusive worldwide license to a proprietary screening technology, which screens food and plant extracts for their impact on gene expression associated with the onset or proliferation of cancer, arthritis, obesity, and other human diseases. Through the use of its technology, the Company has identified ingredients that confer quantifiable health benefits that will be the basis for evidence-based claims for its customers in the food industry. WellGen's goal is to become a significant player in the US $78 billion functional foods market that is growing at a rate of 8.4% per year.
Amphion's fully-diluted ownership stake in WellGen was 17.39% as of 31 December 2006.
Management
Dr. Kathleen P. Mullinix, President and Chief Executive Officer
Robert J. Bertoldi, Chief Financial Officer
Patricia Lucas-Schnarre, Vice President of Marketing and Product Development
Catherine Segal, Rph, Vice President of Business Development
Board of Directors
Richard Laster, Chairman - Former Chief Executive Officer, DNA Plant Technology Corp.
Robert J. Bertoldi - President and Chief Financial Officer, Amphion Innovations plc
Irwin Engelman - Former Chief Financial Officer, General Foods Corp.
Dr. Leif Kjargaard - Senior VP, Danisco A/S
Scott Korman - Chief Executive Officer, Best Manufacturing
Richard C.E. Morgan - Chief Executive Officer, Amphion Innovations plc
Dr. Kathleen Mullinix - President and Chief Executive Officer,WellGen, Inc.
Dr. WilliamSharp - ConsultingManaging Director, Global Institute for Bioexploration of Rutgers University
Beijing Med-Pharm, Corporation
Beijing Med-Pharm (NASDAQ: BMP) helps U.S. and European pharmaceutical companies wishing to enter the Chinese marketplace. Beijing Med-Pharm offers an array of services designed to establish a market for western pharmaceuticals and to then fulfill that market through a comprehensive distribution plan.
Beijing Med-Pharm is a US-managed and US-listed company.
Management
David (Xiao Ying) Gao, President and Chief Executive Officer
Fred Powell, Chief Financial Officer
Dr. Byron Wang, Vice President, Sales and Marketing
Yong Guo, General Manager, Beijing Wanwei Pharmaceutical
Dr. Robert Wang, New Business Development
Richard Liu, Manager, Business Development
Frank Xu, National Sales Manager
Bin Duan, Marketing Manager
Amy Zhou, Director, Human Resources, China
Board of Directors
Martyn Greenacre, Chairman – Former Chairman, Europe, SmithKline Beecham
David (Xiao Ying) Gao – President and Chief Executive Officer, Beijing Med-Pharm
Michel Y. de Beaumont – Founder, American Equities Overseas
Jack M. Ferraro – Formerly Director, Neuberger Berman
Frank J. Hollandoner – Doughty Hanson & Co.
Dr. John W. Stakes - Director Specialty Care Development, Harvard Medical School and
Massachusetts General Hospital
Albert Yeung – Formerly Senior Executive, China, Global Pharmaceutical Companies (including J&J, Xian-Janssen, GSK, and BMS)
Axcess, Inc.
AXCESS International, Inc. (OTCBB: AXSI) (“AXCESS”) provides active Radio Frequency Identification (RFID) and Real Time Location Systems (RTLS) solutions that locate, track, monitor, count, and protect people, assets, and vehicles. The markets of primary interest for the company include enterprise and manufacturing, hospitality, government, defense, transport, logistics, education, healthcare, and banking. IDTechEX, an independent research firm, projects that AXCESS’ main market for Active RFID, RTLS and multifunctional tracking devices will sustain a 28% compounded annual growth rate through 2016 and reach a global market of US $6.8 billion. This represents a 12-fold increase for the market from its present size.
Amphion’s fully-diluted ownership stake in AXCESS was 8.55% as of 31 December 2006.
Management
Allan Griebenow, President and Chief Executive Officer
Allan L. Frank, Vice President and Chief Financial Officer
Raj Bridgelall, Vice President of Engineering
Ray Cavanagh, Vice President of Sales
Ben Donohue, Vice President of Business Development
Board of Directors
Richard C.E. Morgan, Chairman - Chief Executive Officer, Amphion Innovations plc
Robert J. Bertoldi - President and Chief Financial Officer, Amphion Innovations plc
Paul J. Coleman Jr. - President and Chief Executive Officer, Girvan Institute of Technology
Allan Griebenow - President and Chief Executive Officer, AXCESS International, Inc.
Robert F. Hussey - Director, Digital Lightwave, Inc., Board, HC Wainwright & Co.
FireStar Software, Inc.
FireStar Software, Inc. ("FireStar") develops software that assists institutions in automating business transactions between multiple companies. FireStar addresses a very large, existing market for connectivity products. Their product automatically enables various types of software systems to pass data back and forth without costly and time-consuming maintenance or new software development. Research firm Gartner, Inc. estimates the market for integration software to be in excess of US $6.5
billion per year. The key segments FireStar is targeting with its flagship product, called EdgeNode™, are electronic trading, payment solutions, and healthcare informatics.
Amphion's fully-diluted ownership stake in FireStar was 10.75% as of 31 December 2006.
Management
Kenneth Lord, Chief Executive Officer
Chris Sanders, Vice President of Marketing and Business Development
Mark Eisner, Chief Technical Officer
Charley O'Neill, Vice President of Development
Gabriel Oancea, Chief Architect
Board of Directors
Richard C.E. Morgan, Chairman - Chief Executive Officer, Amphion Innovations plc
Robert Anthonyson - Board of Directors, Stanford Business School Trust, Sunapee River-way Corp.
Joseph R. Flicek - Managing Director, Amphion Innovations plc
Kenneth Lord - Chief Executive Officer, FireStar Software, Inc.
Raymond P. McKenzie - Private Investor, Geninvest Ltd.
Durham Scientific Crystals, Ltd.
Durham Scientific Crystals, Ltd. (“DSC”) is a spin out from Durham University (UK) focused on the application of patented, unique semi-conducting materials to the field of medical imaging. DSC produces radically improved and more cost effective semiconductor materials than are currently available, which are used in detectors for medical, security, and defence digital x-ray imaging. These materials have the potential to revolutionise themedical x-ray imagingmarket by enabling the transition fromanalogue to digital, dramatically improving the screening of baggage in airports and railways, and allowing the manufacture of in-demand handheld scanners. DSC has a strong and growing IP (patent) portfolio.
The market for crystals produced from liquid is currently US $100 million per year. The addressable market, where lower quality and less expensive solutions are currently in use, is significantly higher, and will be approximately US $400 million by the end of 2007.
Amphion’s fully-diluted ownership stake in DSC was 26.24% as of 31 December 2006.
Management
Dr. Arnab Basu, Managing Director
Dr. Ben Cantwel, Technical Manager
Dr. J.T. Mullins, Manager, Research and Development
Board of Directors
Prof. Brian Tanner, Chairman - Professor of Physics, University of Durham
Dr. Arnab Basu - Managing Director, Durham Scientific Crystals Ltd.
Dr. A.W. Brinkman - Reader, University of Durham
Richard C.E. Morgan - Chief Executive Officer, Amphion Innovations plc
Prof. Max Robinson - Enterprise Manager, University of Durham
Jerel Whittingham - Managing Director, Amphion Innovations plc
m2m Imaging Corporation
m2m Imaging Corporation (“m2m”) A spin-out of Columbia University and the University of Queensland (Australia), m2m specialises in developing high performance magnetic resonance imaging (“MRI”) coils and accessories, including cryogenic coils, that allow for enhanced imaging without escalating costs. Formerly known as Supertron Technologies, Inc., the new combined company was formed in November 2006 when New Jersey-based Supertron Technologies acquired Spin Systems of Australia. Ultimately, enhanced images are necessary for better disease detection and faster drug discovery, and this need has created a strong demand for solutions, such as the cryogenic coil, that enable better images without creating added cost.
m2m secured US $3.5 million in an oversubscribed Series C financing in 2006.
Amphion’s fully-diluted ownership stake in m2m was 22.81% as of 31 December 2006.
Management
C. Richard Hullihen, Chief Executive Officer
Dr. Erzhen Gao, Chief Scientist
Cameron Barnard, Marketing and Business Development Manager
Kurt Luescher, Manager Operations, Australia
Board of Directors
Robert J. Bertoldi, Chairman - President & Chief Financial Officer, Amphion Innovations plc
Thomas Blum - Managing Director, GC Andersen Partners LLC
Joseph R. Flicek - Managing Director, Amphion Innovations plc
C. Richard Hullihen - Chief Executive Officer, m2m Imaging Corp.
Daniel Rice - President and Chief Executive Officer, Mayport Venture Partners
Zev Rosenzweig - Retired Vice President, Military Aviation Training for Bombardier Inc.
Myconostica
Myconostica, Ltd. (“Myconostica”) is a spin-out from the University of Manchester that specialises in a new type of 'molecular' diagnostic test for infectious diseases, particularly life-threatening respiratory fungal infections, allowing much faster and more precise diagnosis. These tests will have significant health-care benefits, such as reducing death rates, shortening recovery times and hospital stay, and reducing the high cost of care for these types of patients. The standard diagnostic tests in clinical use today are slow, insensitive, and complex, often taking several days for results that are of questionable accuracy. A fundamental benefit of Myconostica’s tests is the fact that they are simple and can test for multiple fungi in a single process. The existing market for molecular testing is currently worth more than US $5.6 billion per year and is expected to grow to US $12 billion by 2010. Myconostica’s focus is on testing for respiratory fungal diseases and blood infections, a market that is currently valued at US $400 million per year.
Amphion’s fully-diluted ownership stake in Myconostica was 32.46% as of 31 December 2006.
Management
Jerel Whittingham, Interim Chief Executive Officer
Professor David Denning, Founder and Research Director
Dr. John Thornback, Chief Operating Officer
Nick Montague, Finance Director
Mike Wraith, Director, Operations
Martin Hughes, Senior Manager, Development and Quality
Board of Directors
Professor David Denning, Chairman - Clinician and researcher, Founder of F2G, world authority on fungal infections.
Richard C.E. Morgan - Chief Executive Officer, Amphion Innovations plc
Jerel Whittingham - Managing Director of Amphion Innovations UK Ltd. (a subsidiary of Amphion Innovations plc) and leads their activities in the UK.
Dr. John Thornback - Background in technology businesses in senior management roles, including CEO of diagnostic companies GE/Amersham, Enigma, Resolution, and Medgenix.
